We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Artificial Intelligence Method That Improves Lab Test Management Discussed at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021
Print article
Illustration
Illustration

Results from an evaluation of an artificial intelligence (AI) method that improves test utilization and reimbursement were presented by Patients Choice Laboratories (Indianapolis, IN, USA) at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Of the five billion lab orders submitted each year, at least 20% are considered inappropriate. These inappropriate tests can lead to slower or incorrect diagnoses for patients. Such tests may also not be covered by Medicare if they weren’t meant to be used for particular medical conditions or if they were ordered with the wrong ICD-10 diagnostic codes, which in turn raises health costs.

Patients Choice Laboratories set out to determine if an automated test management system known as the Laboratory Decision System (LDS) could help improve test ordering. The LDS scores potential tests based on medical necessity and testing indication, helping providers minimize test misutilization and select the best tests for a given medical condition.

Using LDS, the researchers re-evaluated a total of 374,423 test orders from a reference laboratory, 48,049 of which had not met the criteria for coverage under Medicare. For 96.4% of the first 10,000 test claims, the LDS ranking system recommended alternative tests that better matched the medical necessity or had a more appropriate ICD-10 code. Of these recommendations, 80.5% would also meet Medicare policies. All of this indicates that the LDS could help correct mistaken or inappropriate lab orders.

“Our study implies that use of the automated test ordering system LDS would be extremely helpful for providers, laboratories, and payers,” said Dr. Rojeet Shrestha, PhD, of Patients Choice Laboratories. “Use of this algorithm-based testing selection and ordering database, which rates and scores potential tests for any given disease based on clinical relevance, medical necessity, and testing indication, would eventually help providers to select and order the right test and reduce over- and under-utilization of tests.”

Related Links:
Patients Choice Laboratories

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.